Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty

Thrombosis and Haemostasis

Volumn 92, Issue 5, 2004, Pages 1012-1017

  Brotman, Daniel J ^a   Jaffer, Amir K ^a   Hurbanek, Jason G ^b   Morra, Nariman ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Arthroplasty; Enoxaparin; Post operative; Venous thromboembolism; Warfarin

Indexed keywords

ENOXAPARIN; HEPARIN; WARFARIN;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; POSTOPERATIVE CARE; POSTOPERATIVE THROMBOSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURGEON; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CASE-CONTROL STUDIES; DRUG EVALUATION; ENOXAPARIN; FEMALE; HUMANS; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; TIME; VENOUS THROMBOSIS; WARFARIN;

EID: 9144244315     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-04-0204     Document Type: Article

References (21)

1. Morris BA, Colwell CW, Hardwick ME. The use of low molecular weight heparins in the prevention of venous thromboembolic disease. Orthop Nurs 1998; 17: 23-9, 77; quiz 30-1.
2. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S-175S.
3. Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb Haemost 1997; 77: 32-8.
4. Gross M, Anderson DR, Nagpal S, et al. Venous thromboembolism prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons. Can J Surg 1999; 42: 457-61.
5. Janku GV, Paiement GD, Green HD. Prevention of venous thromboembolism in orthopaedics in the United States. Clin Orthop 1996: 313-21.
6. Fossler MJ, Barrett JS, Hainer JW, et al. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Am J Health Syst Pharm 2001; 58: 1614-21.
7. Esmon CT, Vigano-D'Angelo S, D'Angelo A, et al. Anticoagulation proteins C and S. Adv Exp Med Biol 1987; 214: 47-54.
8. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6.
9. Francis CW, Pellegrini VD, Jr., Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997; 79: 1365-72.
10. Freedman KB, Brookenthal KR, Fitzgerald RH, Jr., et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000; 82-A: 929-38.
11. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 1994; 76: 1174-85.
12. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med 1997; 157: 298-303.
13. Stern SH, Wixson RL, O'Connor D. Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. J Arthroplasty 2000; 15: 153-8.
14. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-12.
15. Comp PC, Voegeli T, McCutchen JW, et al. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group. Orthopedics 1998; 21: 1123-8.
16. Howard AW, Aaron SD. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials. Thromb Haemost 1998; 79: 902-6.
17. Hull RD, Pineo GF, MacIsaac S. Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res 2001; 101: V155-62.
18. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124: 619-26.
19. Hamulyak K, Lensing AW, van der Meer J, et al. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb Haemost 1995; 74: 1428-31.
20. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001; 161: 1952-60.
21. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med 2002; 162: 1966-71.